White Paper

From coverage to cost-control: GLP-1 alternatives for weight loss

While GLP-1s have helped many people on their weight loss journeys, the growing demand for this class of drugs has led employers to experience a slew of challenges. As a result, organizations are currently grappling with a critical decision—whether or not to provide coverage.

This white paper covers:

• An introduction to alternative anti-obesity medications (AOMs) and step therapy
• How to establish effective GLP-1 cost-control measures
• The importance of investing in weight care with a comprehensive approach
• How personalization unlocks a more effective path to weight loss for patients